Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety. (27th May 2020)

• Record Type: Journal Article
• Authors: Kuznietsova, Halyna; Dziubenko, Natalia; Byelinska, Iryna; Hurmach, Vasyl; Bychko, Andriy; Lynchak, Oksana; Milokhov, Demyd; Khilya, Olga; Rybalchenko, Volodymyr
• Is Part Of: Journal of drug targeting. Volume 28:Number 5(2020)
• Page Start: 547
• Page End: 563
• Publication Date: 2020-05-27
• Subjects: Pyrrole derivatives -- EGFR -- VEGFR -- lipid membranes -- colonic inflammation -- colon cancer -- redox state -- haematopoiesis; Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.1080/1061186X.2019.1703189
• Languages: English
• ISSNs: 1061-186X

Abstract

Abstract: Pyrrole derivatives (PDs) chloro-1-(4-chlorobenzyl)-4-((3-(trifluoromethyl)phenyl)amino)-1H-pyrrole-2, 5-dione (MI-1) and 5-amino-4-(1, 3-benzothyazol-2-yn)-1-(3-methoxyphenyl)-1, 2-dihydro-3H-pyrrole-3-one (D1) were synthesised as inhibitors of several protein kinases including EGFR and VEGFR. The aim of the study was to reveal the exact mechanisms of PDs' action EGFR and VEGFR are involved in. We observed, that both PDs could bind with EGFR and VEGFR and form stable complexes. PDs entered into electrostatic interactions with polar groups of phospholipid heads in cell membrane, and the power of interaction depended on the nature of PD radical substituents (greater for MI-1 and smaller for D1). Partial intercalation of MI-1 into the membrane hydrophobic zone also occurred. PDs concentrations induced apoptosis in malignant cells but normal ones had different sensitivity to those. MI-1 and D1 acted like antioxidants in inflamed colonic tissue, as evidenced by reduce of lipid and protein peroxidation products (by 43–67%) and increase of superoxide dismutase activity (by 40 and 58%) with restoring these values to control ones. MI-1 restored reduced haemoglobin and normalised elevated platelets and monocytes in settings of colorectal cancer, whereas D1 normalised only platelets. Thus, MI-1 and D1 could be used as competitive inhibitors of EGFR and VEGFR and antioxidants, which might contribute to realisation of their anti-inflammatory, proapoptotic and antitumor activity.